diazepam has been researched along with Acute Confusional Senile Dementia in 40 studies
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.
diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "Humanin (HN) is an endogenous 24-residue peptide." | 1.46 | Humanin ameliorates diazepam-induced memory deficit in mice. ( Maruyama, T; Murakami, M; Nagahama, M; Niikura, T, 2017) |
| "Dementia is one of the age related mental problems and a characteristic symptom of various neurodegenerative disorders including Alzheimer's disease." | 1.33 | Evaluation of nootropic potential of Ocimum sanctum Linn. in mice. ( Joshi, H; Parle, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (7.50) | 29.6817 |
| 2010's | 32 (80.00) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sang, Z | 12 |
| Li, Y | 11 |
| Qiang, X | 10 |
| Xiao, G | 7 |
| Liu, Q | 2 |
| Tan, Z | 12 |
| Deng, Y | 11 |
| Luo, L | 6 |
| Yang, X | 5 |
| Zheng, Y | 4 |
| Cao, Z | 6 |
| Su, F | 2 |
| Ai, J | 1 |
| Xu, R | 5 |
| Song, Q | 5 |
| Pan, W | 2 |
| Wang, K | 8 |
| Ma, Q | 4 |
| Yu, L | 4 |
| Yang, Y | 1 |
| Bai, P | 2 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Li, X | 2 |
| Liu, W | 9 |
| Wang, H | 6 |
| Ye, M | 2 |
| Han, X | 2 |
| Xu, YX | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 2 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 2 |
| Li, J | 2 |
| Zhang, HY | 1 |
| Mao, F | 2 |
| Yang, J | 3 |
| Zhang, X | 2 |
| Liu, H | 4 |
| Yang, Z | 2 |
| Kumar, D | 1 |
| Gupta, SK | 1 |
| Ganeshpurkar, A | 1 |
| Gutti, G | 1 |
| Krishnamurthy, S | 1 |
| Modi, G | 1 |
| Singh, SK | 1 |
| Xu, Y | 1 |
| Zhang, J | 1 |
| Wang, W | 1 |
| Qiu, X | 1 |
| Zhang, H | 1 |
| Boutin, S | 1 |
| Roy, J | 1 |
| Maltais, R | 1 |
| Alata, W | 3 |
| Calon, F | 4 |
| Poirier, D | 1 |
| Tian, C | 1 |
| Li, W | 1 |
| He, Y | 2 |
| Ye, C | 1 |
| Shi, J | 4 |
| Zhang, P | 3 |
| Zhu, G | 2 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Wang, M | 1 |
| Liu, T | 2 |
| Chen, S | 2 |
| Wu, M | 1 |
| Han, J | 1 |
| Li, Z | 2 |
| Du, J | 1 |
| Xing, S | 1 |
| Li, R | 1 |
| Mi, J | 1 |
| Zhou, Y | 1 |
| Wu, A | 1 |
| Umeda, T | 1 |
| Kimura, T | 1 |
| Yoshida, K | 1 |
| Takao, K | 1 |
| Fujita, Y | 1 |
| Matsuyama, S | 1 |
| Sakai, A | 1 |
| Yamashita, M | 1 |
| Yamashita, Y | 1 |
| Ohnishi, K | 1 |
| Suzuki, M | 1 |
| Takuma, H | 1 |
| Miyakawa, T | 1 |
| Takashima, A | 1 |
| Morita, T | 1 |
| Mori, H | 1 |
| Tomiyama, T | 1 |
| Kurlawala, Z | 1 |
| Roberts, JA | 1 |
| McMillan, JD | 1 |
| Friedland, RP | 1 |
| Dhikav, V | 1 |
| Anand, KS | 1 |
| Do, TM | 2 |
| Dodacki, A | 1 |
| Traversy, MT | 1 |
| Chacun, H | 1 |
| Pradier, L | 1 |
| Scherrmann, JM | 1 |
| Farinotti, R | 1 |
| Bourasset, F | 2 |
| Mitsueda, T | 1 |
| Nakaya, Y | 1 |
| Hagiwara, M | 1 |
| Manabe, T | 1 |
| Matsui, M | 1 |
| Quiroga, C | 1 |
| Chaparro, RE | 1 |
| Karlnoski, R | 1 |
| Erasso, D | 1 |
| Gordon, M | 1 |
| Morgan, D | 1 |
| Bosco, G | 1 |
| Rubini, A | 1 |
| Parmagnani, A | 1 |
| Paoli, A | 1 |
| Mangar, D | 1 |
| Camporesi, EM | 1 |
| Ye, Y | 1 |
| St-Amour, I | 1 |
| Vandal, M | 1 |
| Murakami, M | 1 |
| Nagahama, M | 1 |
| Maruyama, T | 1 |
| Niikura, T | 1 |
| Ouellet, M | 1 |
| Tremblay, C | 1 |
| Julien, C | 1 |
| Oddo, S | 1 |
| LaFerla, F | 1 |
| Tampellini, D | 1 |
| Capetillo-Zarate, E | 1 |
| Dumont, M | 1 |
| Huang, Z | 1 |
| Yu, F | 1 |
| Lin, MT | 1 |
| Gouras, GK | 1 |
| Joshi, H | 1 |
| Parle, M | 1 |
| Kálmán, J | 1 |
| Palotás, M | 1 |
| Pákáski, M | 1 |
| Hugyecz, M | 1 |
| Janka, Z | 1 |
| Palotás, A | 1 |
| Weingartner, H | 1 |
| Foster, NL | 1 |
| VanDerSpek, AF | 1 |
| Aldrich, MS | 1 |
| Berent, S | 1 |
| Hichwa, RH | 1 |
| Sackellares, JC | 1 |
| Gilman, S | 1 |
| Agranoff, BW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
40 other studies available for diazepam and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Rel | 2018 |
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2018 |
Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.
Topics: 17-Hydroxysteroid Dehydrogenases; 5-alpha-Dihydroprogesterone; Alzheimer Disease; Enzyme Inhibitors; | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents.
Topics: Alzheimer Disease; Animals; Cognition; Drug Design; Enzyme Inhibitors; Glucose; Glycogen Synthase Ki | 2021 |
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Biphenyl Compounds; Butyrylcholi | 2022 |
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholin | 2022 |
Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer's disease: analysis of Osaka mutation-knockin mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Diazepam; Disease Models, Animal; | 2017 |
Diazepam Toxicity Presenting as a Dementia Disorder.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Diagnosis, Differential; Diazepam; Humans; Male; Memory Di | 2018 |
Acute dystonic reaction with rivastigmine.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Diazepam; Dose-Response Re | 2013 |
Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barrier; Brain; | 2014 |
[Case of an elderly woman with dementia showing episodic involuntary movement of the tongue].
Topics: Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Diagnosis, Differential; Diazepam; Drug Thera | 2014 |
Effects of repetitive exposure to anesthetics and analgesics in the Tg2576 mouse Alzheimer's model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analgesics; Anesthetics; A | 2014 |
Human apolipoprotein E ɛ4 expression impairs cerebral vascularization and blood-brain barrier function in mice.
Topics: Alzheimer Disease; Animals; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Blood-Brain Bar | 2015 |
Humanin ameliorates diazepam-induced memory deficit in mice.
Topics: Alzheimer Disease; Animals; Anticonvulsants; Cognition; Diazepam; Disease Models, Animal; Intracellu | 2017 |
Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Basement Membrane; Blood Vessels; Brain; Brain Ch | 2009 |
Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Cerebral Cortex; Diazepam; Fem | 2010 |
Evaluation of nootropic potential of Ocimum sanctum Linn. in mice.
Topics: Alzheimer Disease; Amnesia; Animals; Dementia; Diazepam; Dose-Response Relationship, Drug; Humans; M | 2006 |
Unchanged rat brain amyloid precursor protein levels after exposure to benzodiazepines in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anesthesia, General; Animals; Antibodies, Monoclonal; Benz | 2006 |
Models of memory dysfunctions.
Topics: Adult; Aged; Alcohol Amnestic Disorder; Alzheimer Disease; Amnesia; Attention; Attention Deficit Dis | 1985 |
The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Deoxyglucose; Diazepam; Female; Fluorodeoxyglucos | 1987 |